Show menu
Health is the lack of internal interference for life
Odessa(048) 777-29-50
Kyiv(044) 455-84-42

The Ministry of Health has approved clinical trials of the effectiveness of "Amiksin" in the treatment of COVID-19

The Ministry of Health has approved clinical trials of the effectiveness of

InterChem received the approval of the Ministry of Health for conducting clinical trials of the effectiveness of the antiviral drug Amiksin in the treatment of COVID-19. The corresponding order of the Ministry of Health was signed on May 14.

The company initiated a clinical trial, as the drug had previously shown efficacy against a number of dangerous viral infections. In addition, the active substance Amiksin - tiloron - has antiviral activity against a number of strains of ordinary coronaviruses, which was shown in the course of preclinical studies.

Also, several international research centers have already conducted and continue to conduct tilorone tests for the SARS-CoV-2 coronavirus. According to the company's general director Anatoly Reder, Amiksin is considered as a potentially effective remedy for COVID-19 not only at InterChem, but also in the research community abroad. Similar studies were conducted at the Pasteur Institute (South Korea), and work is still ongoing at two research centers in the United States.

“Based on the data of preclinical studies demonstrating the antiviral effect of tilorone against SARS-CoV-2, we applied to the Ministry of Health of Ukraine for approval of a phase 3 clinical study to expand the range of use of Amiksin and obtain evidence of its efficacy and safety for treating patients with COVID-19, ”Raeder said.

Clinical trials of Amiksin will be carried out by research centers in three cities of Ukraine, in general, it may take 3-4 months from the date of receipt of permission from the Ministry of Health to conduct it.

“The duration of the study will primarily depend on the speed of patient recruitment. At this stage, it is planned to include more than 60 volunteers in the study, who, according to the severity of the disease, will be on self-isolation and undergo outpatient treatment, ”the InterChem CEO said.

According to him, the research doctors who confirmed their readiness to conduct this study are highly motivated, first of all, by their scientific interest and the opportunity to contribute to the search for a solution to the medical and social problem that has become so urgent for the whole world, which the new coronavirus has become.